Dementia Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The dementia drugs market size was valued at USD 17.46 billion in 2025 and is estimated to grow from USD 18.53 billion in 2026 to reach USD 24.92 billion by 2031, at a CAGR of 6.11% during the forecast period (2026-2031). This report is Segmented by Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and More), Indication (Alzheimer's Disease, Parkinson's Disease Dementia, and More), Route of Administration (Oral, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Dementia Drugs Market Trends and Insights

Ageing Population & Dementia Prevalence Surge

Rapid population ageing is swelling the dementia drugs market as the 65-plus cohort expands faster than any other age group. Dementia incidence doubles roughly every five years after 65, and the World Health Organization projects global cases will triple by 2050. Japan, South Korea, Italy, and Germany exhibit the most acute near-term prevalence spikes, whereas India, Brazil, and Indonesia are expected to encounter steeper late-decade surges in absolute patient numbers. Governments that view dementia as a socioeconomic threat are allocating larger budgets to early diagnosis, caregiver support, and research infrastructure. Insurers are increasingly reimbursing biomarker-guided interventions, thereby enlarging the treated pool and reinforcing prescription growth. Collectively, these dynamics anchor a structurally long-run expansion path for the dementia drugs market.

Approvals of Disease-Modifying Anti-Amyloid Therapies

The 2024 FDA nod for Eli Lilly’s Kisunla and the 2025 European authorization of Eisai’s Leqembi verify the amyloid hypothesis after decades of setbacks. These milestones convert pent-up demand for disease-modifying options into realized sales, catalyzing the development of infusion centers, diagnostic PET capacity, and monitoring pathways. Conditional approvals in certain jurisdictions create tiered pricing but also stimulate value-based contracts that reward real-world cognitive preservation. Three-year Leqembi data demonstrating sustained benefits further strengthen physician confidence. Collectively, these factors inject momentum into the dementia drugs market and spur pipeline diversification into amyloid-plus-tau combination regimens.

High Clinical-Trial Failure Rates & Investment Risk

Historic Alzheimer’s attrition exceeds 90%, eclipsing oncology and cardiovascular benchmarks. Failures in 2024 by Roche, Sage, and Otsuka reaffirm investor caution, which in turn elevates hurdle rates and slows private funding. Neurological endpoints, placebo effects, and heterogeneous patient biology complicate statistical powering, pushing costs beyond USD 1 billion per Phase 3 program. While adaptive trial designs and digital biomarkers promise efficiencies, the risk-reward calculus still curtails capital inflows, restraining the dementia drugs market from achieving faster growth.

Other drivers and restraints analyzed in the detailed report include:

• Growing Adoption of Diagnostic Biomarkers & PET Tracers
• Digital Therapeutics & Combination Regimens Emerging
• Stringent HTA / Reimbursement Hurdles

Segment Analysis

Cholinesterase inhibitors maintained a commanding 50.12% share of the dementia drugs market in 2025, affirming their role as front-line management for mild to moderate Alzheimer’s disease. Nonetheless, anti-amyloid monoclonal antibodies recorded the category’s fastest expansion, supported by a 6.78% CAGR outlook and fresh approvals across North America, Europe, and South Korea. NMDA receptor antagonists continue to address moderate-to-severe stages but face limited differentiation. Pipelines centred on anti-tau and kinase inhibitors have gained FDA Fast Track tags, broadening commercial optionality. Production scalability and infusion infrastructure remain the primary gating factors for monoclonal antibody prescriptions, yet sustained cognitive benefit data are converting neurologists and solidifying reimbursement support, thereby deepening anti-amyloid penetration within the dementia drugs market.

Looking ahead, competitive dynamics hinge on portfolio breadth and manufacturing agility. Johnson & Johnson’s posdinemab received Fast Track status in January 2025, prompting rivals to accelerate combination trials pairing amyloid and tau mechanisms. Bristol Myers Squibb’s repurposing of Cobenfy signals a broader move toward multi-indication platforms that straddle psychosis, agitation, and cognition. Amid these shifts, the dementia drugs market size for anti-amyloid drugs is forecast to double by 2030, whereas legacy categories plateau, forcing incumbents to diversify or risk share erosion.

Alzheimer’s disease retained a formidable 60.62% share of the dementia drugs market in 2025, bolstered by symptomatic and disease-modifying options. Yet mild cognitive impairment has surfaced as the fastest-growing niche, tracking a 6.92% CAGR through 2031 as biomarker-guided diagnosis expands in primary care. Cognivue Clarity and CognICA screenings differentiate MCI from normal ageing with high specificity, opening an earlier therapeutic window. Parkinson’s disease dementia and Lewy-body conditions maintain meaningful, though smaller, treatment footprints; Ambroxol and other repositioned agents in Phase 3 could lift penetration by late decade.

Early-stage intervention raises pivotal questions on treatment length, payer budgets, and patient selection. U.S. Medicare’s draft coverage restricts anti-amyloid infusion to biomarker-confirmed MCI or mild dementia, underscoring the linkage between diagnostics and revenue growth. In Asia-Pacific, national reimbursement is contingent on local cost-utility files, but ageing populations in Japan and South Korea will swell absolute candidate pools.

Complete Report Scope:

• By Drug Class
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Anti-Amyloid Monoclonal Antibodies
  • Multi-target Kinase & Other Emerging Classes
• By Indication
  • Alzheimer’s Disease
  • Parkinson’s Disease Dementia
  • Lewy-Body & Frontotemporal Dementias
• By Route of Administration
  • Oral
  • Intravenous
  • Transdermal
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America holds 42.63% of global revenue in 2025 in the dementia drugs market, sustained by favorable reimbursement, early regulatory endorsements, and extensive clinical research infrastructure. Medicare’s national coverage determination for amyloid PET imaging removes a critical barrier, allowing more accurate patient selection and reinforcing payer confidence in cognitive benefit trajectories. Canada’s deliberative approach stresses cost-utility, but provincial pilot programmes are paving access for biomarker-confirmed mild cognitive impairment. Mexico, although smaller, is witnessing the rise of private neurology networks that import U.S.-approved biologics for high-income cohorts, indicating an emergent cross-border niche.

Asia-Pacific is the fastest-growing region at 9.30% CAGR through 2031. Asia-Pacific’s momentum is grounded in sheer demographic scale alongside rising per-capita healthcare spend. Japan’s super-aged society drives near-term volume, supported by a strong domestic diagnostics industry capable of supplying amyloid and tau tracers. South Korea’s single-payer system has quickly integrated Leqembi under risk-sharing reimbursement, demonstrating institutional readiness to embrace expensive disease-modifying therapies. China remains a wildcard: its large patient pool offers unmatched upside, yet evolving regulatory rules and supply-chain frictions introduce execution risks. India and Indonesia will initially prioritise symptomatic generics, but rising middle-class affordability foreshadows long-run biologic demand that could reshape the dementia drugs market.

Europe delivers steady but moderated growth. National HTA bodies continue to constrain list prices, compelling companies to accept confidential discounts or contingent-value agreements. Germany’s rapid adoption of new diagnostics balances slower therapeutic uptake in the UK and Spain. France’s national dementia plan incorporates caregiver stipends, indirectly easing treatment adoption by offsetting ancillary costs. Eastern European markets trail in both diagnostic capacity and reimbursement scope, yet EU structural funds earmarked for geriatric care upgrades may lift baseline infrastructure. Overall, Europe’s policy environment favours gradual rather than explosive contributions to the dementia drugs market size.

List of Companies Covered in this Report:

• Biogen
• Eisai
• Eli Lilly and Company
• Novartis
• Pfizer
• Johnson & Johnson
• Roche
• Otsuka
• Lundbeck A/S
• Merck
• Abbvie
• Amgen
• AC Immune SA
• Cassava Sciences, Inc.
• Cognition Therapeutics
• BioArctic AB
• Sun Pharma Advanced Research Company

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support